{"id":53406,"date":"2025-10-03T13:29:08","date_gmt":"2025-10-03T13:29:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/53406\/"},"modified":"2025-10-03T13:29:08","modified_gmt":"2025-10-03T13:29:08","slug":"scientists-just-cracked-the-mystery-of-why-cancer-immunotherapy-fails","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/53406\/","title":{"rendered":"Scientists just cracked the mystery of why cancer immunotherapy fails"},"content":{"rendered":"<p id=\"first\">In what experts are calling a paradigm-shifting landmark study, scientists from The Ohio State University Comprehensive Cancer Center &#8211; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC &#8211; James) report key findings about the underlying mechanisms of immune system stress response to protein misfolding, launching a new approach to cancer immunotherapy treatment targeting the protein production cycle.<\/p>\n<p>For this study, OSUCCC &#8211; James researchers sought to answer a long-held question: Why do T cells, which are crucial for fighting infections and recognizing cancer, sometimes become &#8220;exhausted&#8221; and lose their effectiveness?<\/p>\n<p>In this comprehensive preclinical study, researchers revealed a hidden vulnerability in exhausted T cells: they are overwhelmed by misfolded proteins that ignite a previously unrecognized stress pathway, now named TexPSR (proteotoxic stress response in T-cell exhaustion).<\/p>\n<p>Unlike ordinary stress responses that slow protein production to help cells regain balance, TexPSR drives protein synthesis into overdrive. The result is a relentless buildup of misfolded proteins, stress granules, and toxic aggregates \u00be similar to the amyloid plaques seen in Alzheimer&#8217;s disease. This overload poisons the T cells, crippling their ability to attack tumors.<\/p>\n<p>Nature Reviews Immunology, a leading opinion journal in the field, described this phenomenon as a &#8220;proteotoxic shock.&#8221; Strikingly, when researchers blocked key drivers of TexPSR in preclinical models, exhausted T cells recovered their function and cancer immunotherapy became markedly more effective.<\/p>\n<p>&#8220;T-cell exhaustion is the biggest roadblock to cancer immunotherapy. Our study results present a surprising and exciting answer to this fundamental problem and could be critical to improving future scientific advances in the field of engineered cancer drug therapies to harness the immune system,&#8221; said Zihai Li, MD, PhD, senior study author and founding director of the Pelotonia Institute for Immuno-oncology (PIIO) at the OSUCCC &#8211; James.<\/p>\n<p>Li, who also serves as Deputy Director for Translational Research at the OSUCCC &#8211; James and holds the Klotz Memorial Chair in Cancer Research, has studied the link between protein folding and immunity for over three decades. He emphasized: &#8220;Researchers worldwide are tackling T-cell exhaustion through studying genetics, epigenetics, metabolism and others, but the role of protein quality control has been largely overlooked &#8212; until now.&#8221;<\/p>\n<p>The Ohio State cancer research team also found that high levels of TexPSR in T cells from cancer patients were linked to poor clinical responses to immunotherapy. This suggests that targeting TexPSR could be a new way to enhance cancer treatment in the clinics.<\/p>\n<p>&#8220;When T cells become exhausted, they continue creating molecular weapons but then destroy the weapons before they can do their job,&#8221; said Yi Wang, first author and doctoral student in Li&#8217;s laboratory.<\/p>\n<p>The team&#8217;s findings reveal that this self-perpetuating cycle of protein stress is a central driver of T-cell exhaustion, ultimately disabling the function of these immune cells. Notably, the mechanism was validated in multiple preclinical and clinical cancer models &#8212; including lung, bladder, liver cancer, and leukemia &#8212; highlighting its broad relevance across diverse cancer types.<\/p>\n<p>Li and colleagues report their findings in the latest issue of Nature.<\/p>\n","protected":false},"excerpt":{"rendered":"In what experts are calling a paradigm-shifting landmark study, scientists from The Ohio State University Comprehensive Cancer Center&hellip;\n","protected":false},"author":2,"featured_media":53407,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46,40619],"class_list":{"0":"post-53406","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-il","10":"tag-israel","11":"tag-liver-disease-leukemia-alzheimeramp039s-research-healthy-aging-lung-cancer-pharmacology-diseases-and-conditions-bladder-disorders"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/53406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=53406"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/53406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/53407"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=53406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=53406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=53406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}